Abstract:Inflammasomes are intracellular multiprotein complexes that activate inflammatory signaling pathways. Inflammasomes comprise two major classes: canonical inflammasomes, which were discovered first and are activated in response to a variety of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), and non-canonical inflammasomes, which were discovered recently and are only activated in response to intracellular lipopolysaccharide (LPS). Although a larger number of studies have successfully demonstrated that canonical inflammasomes, particularly the NLRP3 inflammasome, play roles in various rheumatic diseases, including rheumatoid arthritis (RA), infectious arthritis (IR), gouty arthritis (GA), osteoarthritis (OA), systemic lupus erythematosus (SLE), psoriatic arthritis (PA), ankylosing spondylitis (AS), and Sjögren's syndrome (SjS), the regulatory roles of non-canonical inflammasomes, such as mouse caspase-11 and human caspase-4 non-canonical inflammasomes, in these diseases are still largely unknown. Interestingly, an increasing number of studies have reported possible roles for non-canonical inflammasomes in the pathogenesis of various mouse models of rheumatic disease. This review comprehensively summarizes and discusses recent emerging studies demonstrating the regulatory roles of non-canonical inflammasomes, particularly focusing on the caspase-11 non-canonical inflammasome, in the pathogenesis and progression of various types of rheumatic diseases and provides new insights into strategies for developing potential therapeutics to prevent and treat rheumatic diseases as well as associated diseases by targeting non-canonical inflammasomes.

What problem does this paper attempt to address?

This paper aims to explore the role of non - classical inflammasomes (especially caspase - 11 non - classical inflammasomes) in rheumatic diseases. Although a large number of studies have demonstrated the role of classical inflammasomes (such as NLRP3 inflammasomes) in various rheumatic diseases, little is still known about the regulatory role of non - classical inflammasomes (such as mouse caspase - 11 and human caspase - 4 non - classical inflammasomes) in these diseases. This article reviews and discusses the recently emerged studies, which show the regulatory role of non - classical inflammasomes, especially caspase - 11 non - classical inflammasomes, in the occurrence and development of various types of rheumatic diseases, and provides new insights into potential strategies for preventing and treating rheumatic diseases and their related diseases by targeting non - classical inflammasomes. Specifically, the paper focuses on the following aspects: 1. **Structure and activation mechanism of inflammasomes**: It introduces the structural composition of caspase - 11 non - classical inflammasomes and how they activate inflammatory signaling pathways by directly sensing intracellular lipopolysaccharide (LPS). 2. **Role of caspase - 11 non - classical inflammasomes in inflammatory arthritis**: It explores the role of caspase - 11 non - classical inflammasomes in rheumatoid arthritis (RA) and gouty arthritis (GA), including their effects on neutrophil migration, apoptosis, and the production of inflammatory cytokines. 3. **Role of caspase - 11 non - classical inflammasomes in osteoarthritis (OA)**: It analyzes the role of caspase - 4 non - classical inflammasomes in LPS - induced chondrocyte apoptosis and their potential contribution to the development of OA. Through these studies, the paper emphasizes the importance of non - classical inflammasomes in rheumatic diseases and provides a theoretical basis for the development of new anti - rheumatic treatment strategies.

Roles of the Caspase-11 Non-Canonical Inflammasome in Rheumatic Diseases

Regulatory Roles of the Caspase-11 Non-Canonical Inflammasome in Inflammatory Diseases

Non-canonical inflammasome activation targets caspase-11

Activation and Pharmacological Regulation of Inflammasomes

Advances in Disease Mechanisms and Translational Technologies: Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases

Inflammasome and Its Therapeutic Targeting in Rheumatoid Arthritis

Caspase-11 mediated inflammasome activation in macrophages by systemic infection of A. actinomycetemcomitans exacerbates arthritis

Noncanonical inflammasomes: Antimicrobial defense that does not play by the rules

Regulation, Activation and Function of Caspase-11 during Health and Disease

Inflammasomes: mechanism of action, role in disease, and therapeutics

Inflammasomes: Key Mediators of Lung Immunity

Mechanisms and Consequences of Noncanonical Inflammasome-Mediated Pyroptosis

The role of inflammasomes in human diseases and their potential as therapeutic targets

The NLRP3 Inflammasome as a Pathogenic Player Showing Therapeutic Potential in Rheumatoid Arthritis and Its Comorbidities: A Narrative Review

The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases

Inflammasomes and human autoimmunity: A comprehensive review

Role of the NLRP3 inflammasome in autoimmune diseases

Inflammasome activation: from molecular mechanisms to autoinflammation

Inflammasomes and their roles in health and disease

Role of Inflammasomes in Kidney Diseases via Both Canonical and Non-canonical Pathways

Inflammasomes: Mechanisms of Action and Involvement in Human Diseases